Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУН «Центр теоретических проблем физико-химической фармакологии» Российской академии наук, Москва, Россия dvoriankova@mail.ru
Список исп. литературыСкрыть список 1. Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565–74. 2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020. DOI: 10.1111/jdv. 16387 3. Zhang Y, Cao W, Xiao M et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acroischemia. Zhonghua Xue Ye Xue Za Zhi 2020; 41: E006. 4. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. DOI: 10.1111/all.14238 5. Zheng Y, Lai W. Dermatology staff participate in fight against Covid-19 in China. J Eur Acad Dermatol Venereol 2020. DOI: 10. 1111/jdv.16390 6. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104 (3): 246–51. 7. Jin Y-H, Lin C, Cheng Z-S et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7: 4. 8. Yan Y, Chen H, Chen L et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for healthcare workers fighting against coronavirus disease 2019. Dermatol Ther 2020; e13310. DOI: 10.1111/dth.13310 9. Lan J, Song Z, Miao X et al. Skin damage among healthcare workers managing coronavirus disease-2019. J Am Acad Dermatol 2020; PII: S0190-9622 (20): 30392–3. DOI: 10.1016/j.jaad.2020. 03.014 10. Lin P, Zhu S, Huang Y et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol 2020. DOI: 10.1111/bjd.19089 11. Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement. Australas J Dermatol 2020. DOI: 10.1111/ajd.13313 12. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395 (10223): 473–5. 13. Baysham AM, Feldman SR. Should patients stop their biologic treat- ment during the COVID-19 pandemic. J Dermatol Treat 2020; 1–2. DOI: 10.1080/09546634.2020.1742438 14. Camus P. The drug-induced respiratory disease website, Pneumotox Online V2.2. http://www.pneumotox.com. Assessed April 7, 2020.